Biotechnology
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Jan. 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-01-12 13:02
5622
Valo Raises $190 Million in Series B Financing and Unveils Select Therapeutic Programs
Details of Initial Therapeutic Programs to be Shared at the 39th J.P. Morgan Healthcare Conference BOSTON, Jan. 11, 2021 /PRNewswire/ -- Valo Health LLC (Valo), the technology company working to transform the drug discovery and development process and accelerate the creation of life-changin...
2021-01-12 12:26
1756
DarwinHealth Scientists Publish Foundational Research Identifying Regulatory Mechanisms Controlling Cancer Cell States and Drug Response
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc., a New York-based biotechnology and cancer drug discovery company announces the January 11, 2021 online publication in Cell of a landmark paper, "A Modular Master Regulator Landscape Controls Cancer Transcriptional Identity,"[1,2] in whic...
2021-01-12 08:21
1802
MedSkin Solutions Dr. Suwelack AG Receives FDA 510(k) Clearance for MatriDerm® - Its Three-Dimensional Acellular Collagen Elastin Dermal Matrix Portfolio
MedSkin Solutions Dr. Suwelack AG announces receiving FDA 510(k) clearance for its flagship Med Care product portfolio MatriDerm®. HAMBURG, Germany, Jan. 12, 2021 /PRNewswire/ -- MatriDerm® is a single-use three-dimensional acellular dermal matrix composed of bovine collagen fibers and bovine el...
2021-01-12 04:38
1251
Happiness Biotech's E-Commerce Business - Happy Buy, Achieved Over 70% Growth in December
NANPING, China, Jan. 11, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that Happy Buy, the Company's wholly-owned subsidiary focusing on e-commerce business, has achiev...
2021-01-11 21:00
6895
PharmAbcine announces a research collaboration with LegoChem Biosciences
DAEJEON, South Korea, Jan. 11, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company has entered into a research collaboration agreement with LegoChem Bioscience...
2021-01-11 21:00
1191
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
SHANGHAI, Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients inGreater China, announced today the closing of a$150 million Series B financing. The round...
2021-01-09 11:06
5607
Gracell Biotechnologies Announces Pricing of Initial Public Offering
SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical ne...
2021-01-08 14:55
9390
Caprion-HistoGeneX Acquires Clinical Logistics Inc., a Virtual Central Specimen Management CRO, and Expands its Support of Clinical Trials Specimen Logistics
MONTREAL, Jan. 7, 2021 /PRNewswire/ -- Caprion-HistoGeneX, a leading global contract research laboratory services provider backed by Arsenal Capital Partners, announced today the acquisition of Clinical Logistics Inc. ("CLI"), a Virtual Central Specimen Management CRO based inHalifax, Canada. The...
2021-01-07 21:20
2336
Dr David Stamler Appointed CEO
MELBOURNE, Australia, Jan. 7, 2021 /PRNewswire/ -- The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of DrDavid Stamler to the role of Chief Executive Office effective immediately. Dr Stamler joined the Company in J...
2021-01-07 21:00
11778
Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies
CAMBRIDGE, Mass. and SUZHOU, China, Jan. 7, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first closing of an oversubscribed$53.5 million Series B+ fina...
2021-01-07 20:31
2568
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
- Ocular Pain, a $10+ billion global market, with significant unmet medical need - License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies IRVINE, California, PARIS, HONG KONG, Jan. 7, 2021 /PRNewswire/ -- IACTA Pharmaceuticals, Inc...
2021-01-07 20:00
2251
VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China
SHANGHAI, Jan. 7, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into theChina market and hoping to provide more Chinese patients quick access to the world's most a...
2021-01-07 18:45
1462
Merck Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics
- Adds to Merck's lipid manufacturing expertise, providing an integrated offering across mRNA value chain - AmpTec's differentiated polymerase chain reaction (PCR)-based technology has shown to have advantages over other technologies for mRNA manufacturing - Diagnostics business focused on produ...
2021-01-07 17:00
4072
Everest Medicines Announces CTA Approval by China NMPA for Phase 3 Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer
SHANGHAI, Jan. 6, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced th...
2021-01-06 21:54
5983
Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
SHANGHAI, Jan. 6, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, announced today th...
2021-01-06 21:52
6266
VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive Funding
AUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it has been awarded additional non-dilutive funding totaling approximately$4 million from the Walloon Region and Namur Invest,Belgium. To date, Agencies from the Walloon Region have a...
2021-01-06 21:25
9504
INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18
- DNA immunotherapy candidate VGX-3100 demonstrated clinically significant reduction of HPV-16/18-associated precancerous vulvar lesions in 63% of treated participants six months after treatment - Phase 2 results indicate that VGX-3100 can be a safe, tolerable and efficacious adjunct to current ...
2021-01-06 21:00
3786
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease
TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-01-06 20:24
5690
JOYSBIO's COVID-19 antigen test kit is capable of detecting the new SARS-COV-2 strain found in the United Kingdom and the United States
BINHAI, Tianjin, Jan. 6, 2021 /PRNewswire/ -- As the world watches a concerning new strain of SARS-COV-2 first identified in theUnited Kingdom, one global biotech company has announced that their antigen test kit can detect the variant. JOYSBIO Biotechnology Co.'s SARS-CoV-2 Antigen Rapid Test K...
2021-01-06 15:11
2355
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5608
